Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | 11. Subsequent Events In July 2026, the Company purchased an active pharmaceutical ingredient from Par Health for use in the manufacture of the Company's product candidate, Haduvio, for approximately $2.4 million. The active pharmaceutical ingredient was delivered in July 2026, and the related payment obligation was outstanding as of the date of this Quarterly Report on Form 10-Q. Michael Heffernan, a member of the Company's board of directors, serves as chairman of the board of directors of Par Health. |